Alembic Pharmaceuticals is currently trading at Rs. 522.00, up by 0.30 points or 0.06% from its previous closing of Rs. 521.70 on the BSE.
The scrip opened at Rs. 522.40 and has touched a high and low of Rs. 526.95 and Rs. 505.00 respectively. So far 1217 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 469.75 on 20-Sep-2017.
Last one week high and low of the scrip stood at Rs. 575.90 and Rs. 505.00 respectively. The current market cap of the company is Rs. 9708.57 crore.
The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 14.34% and 12.98% respectively.
Alembic Pharmaceuticals’ associate company - Rhizen Pharmaceuticals S.A. (Rhizen) has been granted orphan-drug designation by the US Food and Drug Administration (USFDA) for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).
Tenalisib is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: